FDA Approves Bristol Myers Squibb's New Schizophrenia Drug KarXT, Brand Name Cobenfy

Sep 26, 2024, 10:44 PM

The U.S. Food and Drug Administration (FDA) has approved KarXT, a new schizophrenia drug developed by Bristol Myers Squibb, on Thursday. This marks the first new type of treatment for schizophrenia in decades and offers a significant advancement in the management of the mental disorder. KarXT, also known by its brand name Cobenfy, is notable for its effectiveness and milder side effects compared to existing treatments. The drug, approved for oral use, is a major milestone for patients and the pharmaceutical industry, as it brings renewed focus to neuropsychiatric treatments.